PL423673A1 - Kompozycja do podawania doustnego, zastosowanie kompozycji w zapobieganiu i leczeniu mucositis oraz sposób leczenia mucositis - Google Patents

Kompozycja do podawania doustnego, zastosowanie kompozycji w zapobieganiu i leczeniu mucositis oraz sposób leczenia mucositis

Info

Publication number
PL423673A1
PL423673A1 PL423673A PL42367317A PL423673A1 PL 423673 A1 PL423673 A1 PL 423673A1 PL 423673 A PL423673 A PL 423673A PL 42367317 A PL42367317 A PL 42367317A PL 423673 A1 PL423673 A1 PL 423673A1
Authority
PL
Poland
Prior art keywords
composition
mucositis
treatment
prevention
application
Prior art date
Application number
PL423673A
Other languages
English (en)
Inventor
Agata LEWANDOWSKA
Original Assignee
Lewandowska Agata
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lewandowska Agata filed Critical Lewandowska Agata
Priority to PL423673A priority Critical patent/PL423673A1/pl
Priority to PCT/IB2018/059525 priority patent/WO2019106626A1/en
Publication of PL423673A1 publication Critical patent/PL423673A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Przedmiotem zgłoszenia jest kompozycja do podawania doustnego, oraz zastosowanie tej kompozycji w zapobieganiu i leczeniu mucositis oraz sposób leczenia mucositis u pacjentów przed i po leczeniu systemowym, wykorzystujący powyższą kompozycje.
PL423673A 2017-12-01 2017-12-01 Kompozycja do podawania doustnego, zastosowanie kompozycji w zapobieganiu i leczeniu mucositis oraz sposób leczenia mucositis PL423673A1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL423673A PL423673A1 (pl) 2017-12-01 2017-12-01 Kompozycja do podawania doustnego, zastosowanie kompozycji w zapobieganiu i leczeniu mucositis oraz sposób leczenia mucositis
PCT/IB2018/059525 WO2019106626A1 (en) 2017-12-01 2018-11-30 Composition for oral administration, the use of the composition in prevention and treatment of mucositis, and a method of treatment of mucositis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL423673A PL423673A1 (pl) 2017-12-01 2017-12-01 Kompozycja do podawania doustnego, zastosowanie kompozycji w zapobieganiu i leczeniu mucositis oraz sposób leczenia mucositis

Publications (1)

Publication Number Publication Date
PL423673A1 true PL423673A1 (pl) 2019-06-03

Family

ID=65496772

Family Applications (1)

Application Number Title Priority Date Filing Date
PL423673A PL423673A1 (pl) 2017-12-01 2017-12-01 Kompozycja do podawania doustnego, zastosowanie kompozycji w zapobieganiu i leczeniu mucositis oraz sposób leczenia mucositis

Country Status (2)

Country Link
PL (1) PL423673A1 (pl)
WO (1) WO2019106626A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021218998A1 (en) * 2020-02-12 2022-07-28 Dsm Ip Assets B.V. Direct delivery of antioxidants to the gut
CN114982970B (zh) * 2022-01-29 2024-02-09 石药集团中诺药业（泰州）有限公司 一种辅助保护内腔粘膜的营养素含片及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008140335A2 (en) * 2007-05-14 2008-11-20 Fonterra Co-Operative Group Limited Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001024812A1 (en) * 1999-10-06 2001-04-12 N.V. Nutricia USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
DE10057290B4 (de) * 2000-11-17 2004-01-08 Fresenius Kabi Deutschland Gmbh Enteral zu verabreichendes Supplement zur parenteralen Ernährung oder partiellen enteralen/oralen Ernährung bei kritisch Kranken, chronisch Kranken und Mangelernährten
CN101896176A (zh) * 2007-10-14 2010-11-24 佛罗里达大学研究基金公司 改善胃肠道功能的制剂
SG193928A1 (en) * 2011-04-12 2013-11-29 Nestec Sa Nutritional compositions including branched chain fatty acids for improving gut barrier function

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008140335A2 (en) * 2007-05-14 2008-11-20 Fonterra Co-Operative Group Limited Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments
US20110182943A1 (en) * 2007-05-14 2011-07-28 Fonterra Co-Operative Group Limited Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AGATA LEWANDOWSKA, ALICJA ELŻBIETA WOZNIAK, ŻYWIENIE U CHORYCH NA NOWO­TWORY, 2016 *
CHAPKIN, R. S., MECHANISMS BY WHICH DOCOSAHEXAENOIC ACID AND RELATED FATTY ACIDS REDUCE COLON CANCER RISK AND INFLAMMATORY DISORDERS OF THE INTES­TINE, 2008 *
IZABELA DANIEL, JOANNA SADOWSKA, PRZECIWNOWOTWOROWE DZIAŁANIE PRODUKT6W ROŚLINNYCH, 2016 *
KOTUNIA A., PIETRZAK P., GUILLOTEAU P., ZABIELSKI R., KWAS MASŁOWY W PRZEWODZIE POKARMOWYM, 2010 *

Also Published As

Publication number Publication date
WO2019106626A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
DOP2017000271A (es) Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t
MX2022001075A (es) Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
MX2020010603A (es) Extracto de cáñamo para tratamiento de dolor en animales.
MX387885B (es) Inhibidores de ezh2 para tratar linfomas.
BR112018013245A2 (pt) método e aparelho para administração óxido nítrico com drogas suplementares
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
MX2025003477A (es) Uso de reboxetina para el tratamiento de narcolepsia
CY1122882T1 (el) Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
MX2021007453A (es) Administracion perineural de resiniferatoxina para el tratamiento del dolor maladaptativo.
MX2021001612A (es) Compuestos utiles en terapia del vih.
GB2564801A (en) Implantable scaffolds for treatment of sinusitis
PH12021551805A1 (en) Treatment of skin lesions and pruritus in prurigo nodularis patients
MX2021004396A (es) Metodos y composiciones para el tratamiento de la mucositis oral.
UA118474C2 (uk) (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
PL423673A1 (pl) Kompozycja do podawania doustnego, zastosowanie kompozycji w zapobieganiu i leczeniu mucositis oraz sposób leczenia mucositis
MX2020008923A (es) Inhibidores de la bomba de protones y métodos de uso en inflamación y cicatrización tisular inducida por quimioradiación.
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
MX2020010338A (es) Uso de calcifediol en pacientes de cirugia bariatrica.
UA116499C2 (uk) (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
IL250852B (en) Periodontal preparation
WO2019126695A3 (en) Methods and pharmaceutical compositions for treating candida auris in blood